

Network Pharmacology-Based Investigation into the Multi-Target Mechanisms of *Nardostachys jatamansi* in the Treatment of Adhd

Dr. Sonu Prakash¹, Dr. Basavaraj Tubaki², Dr. Mahesh Kamate³

¹ PhD Scholar, Faculty of Ayurveda, KLE Academy of Higher Education and Research.

Email: sp2277423@gmail.com

² Professor & Head, Department of Kayachikitsa, Kaher's Shri BMK Ayurveda Mahavidyalaya, Belagavi.

Email: basavarajtubaki.kaher@kleayurworld.edu.in

³ Professor & Head, Department of Pediatric Neurology, Jawaharlal Nehru Medical College, Belagavi.

Email: drmaheshkamate@gmail.com

Received: 28th Feb, 2026 | **Revised:** 14th Mar, 2026 | **Accepted:** 4th Apr, 2026 | **Available Online:** 20th Apr, 2026

ABSTRACT

Background: Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. Current treatments may have limitations and side effects. *Nardostachys jatamansi* is traditionally used for neurological conditions.

Objective: To explore the multi-target mechanism of *N. jatamansi* in ADHD using a network pharmacology approach.

Methods: Phytochemicals were screened using SwissADME. Target proteins were predicted using SwissTargetPrediction. ADHD-related genes were obtained from GeneCards. Overlapping targets were analyzed using STRING database. Functional enrichment was performed using Metascape.

Results: Thirty overlapping targets were identified. Key hub genes included BDNF, DRD2, DRD4, SLC6A4, COMT, MAOA, TNF, and NFKB1. Enrichment analysis showed involvement in neurotransmitter signaling, synaptic transmission, and cAMP pathways. Cluster analysis identified core functional modules. Regulatory and disease enrichment analyses further supported neuronal and psychiatric relevance.

Conclusion: *N. jatamansi* acts through multiple targets related to neurotransmission, neurodevelopment, and inflammation, suggesting its potential role in ADHD management.

Keywords: ADHD, *Nardostachys jatamansi*, Network pharmacology, Multi-target mechanism, Neurotransmission.

How to cite this article: Prakash S, Tubaki B, Kamate M. Network Pharmacology-Based Investigation into the Multi-Target Mechanisms of *Nardostachys jatamansi* in the Treatment of Adhd. *Int J Drug Deliv Technol.* 2026;16(30s):682-686. DOI: 10.25258/ijddt.16.30s.63

Source of support: Nil.

Conflict of interest: The authors declare no conflict of interest.

Network Pharmacology-Based Investigation into the Multi-Target Mechanisms of *Nardostachys jatamansi* in the Treatment of ADHD

Introduction

ADHD is a neurodevelopmental disorder affecting both children and adults and is characterized by inattention, hyperactivity, and impulsivity [1]. The disorder is strongly associated with dysregulation of neurotransmitters such as dopamine, serotonin, and norepinephrine [2].


Current pharmacological treatments, although effective, may produce adverse effects and are not suitable for all patients [3]. Therefore, alternative and complementary therapeutic approaches are being explored.

Nardostachys jatamansi is a traditional medicinal plant known for its neuroprotective, anxiolytic, and cognitive-enhancing properties [4]. However, its molecular mechanism in ADHD remains unclear.

Network pharmacology provides a systematic approach to study multi-component and multi-target interactions and has become an important tool in drug discovery [5]. This study aims to investigate the mechanism of *N. jatamansi* in ADHD using this approach.

METHODOLOGY

Figure 1: Workflow of the network pharmacology approach used to investigate the therapeutic mechanisms of *Nardostachys jatamansi* in ADHD.



1. Phytochemical Screening

Phytochemicals were collected and evaluated for pharmacokinetic properties using SwissADME [6]. Compounds with favorable ADME profiles were selected (Table 1).

Table 1: ADME properties and drug-likeness evaluation of selected phytochemicals from *Nardostachys jatamansi*

Compound	GI Absorption	BB	P-gp	CYP	Bioavailability	PA	Leads	Synthetic

Patchouli Alcohol	High	Yes	No	CYP2C9	Yes (violation)	0.55	0	No	3.38
Angelicin	High	Yes	No	CYP2C9, CYP2C19	Yes (violation)	0.55	0	No	3.71
Valerone	High	Yes	No	CYP2C9	Yes (violation)	0.55	0	No	3.06
Nardosinone	High	Yes	No	None	Yes (violation)	0.55	0	Yes	4.82
Jatamol A	High	Yes	No	CYP2C9, CYP2C19	Yes (violation)	0.55	0	No	3.71
Pinorsinol	High	Yes	Yes	CYP2D6, CYP3A4	Yes (violation)	0.55	0	No	3.99
Cubebol	High	Yes	No	CYP2C9, CYP2C19	Yes (violation)	0.55	0	No	4.13
Beta-Eudesmol	High	Yes	No	CYP2C9	Yes (violation)	0.55	0	No	3.38
Jatamsin	High	Yes	No	CYP2C9, CYP2C19, CYP3A4	Yes (violation)	0.55	0	No	4.08
Seychellene	Low	No	No	CYP1A2, CYP2C19	Yes (violation)	0.55	0	No	4.01

Network Pharmacology-Based Investigation into the Multi-Target Mechanisms of *Nardostachys jatamansi* in the Treatment of ADHD

Targets were predicted using SwissTargetPrediction and validated through database cross-referencing.

3. Overlapping Targets

A total of 30 common targets were identified between phytochemicals and ADHD-related genes.

4. PPI Network

The PPI network demonstrated strong interactions among targets, with key hub genes such as BDNF, DRD2, DRD4, and SLC6A4 (Figure 2).


5. Enrichment Analysis

Enrichment analysis revealed significant involvement in neurotransmitter signaling, synaptic transmission, and cAMP signaling pathways (Figure 3 and Figure 4).

6. Cluster Analysis

Cluster analysis identified highly interconnected modules associated with neurotransmitter systems (Figure 5).

Figure 5: Cluster analysis of the PPI network showing highly interconnected modules identified using MCODE.



7. Transcription Factor Analysis

Key transcription factors such as NFKB1, SP1, and NR3C1 were identified, indicating regulatory roles in gene expression (Figure 6).




Figure 6: Transcription factor enrichment analysis highlighting key regulatory elements involved in gene expression.

8. Disease and Cell-Type Enrichment

Disease enrichment analysis showed associations with impulsivity, inattention, and mood disorders (Figure 7).

Cell-type enrichment indicated predominant expression in neuronal populations, especially midbrain neurons (Figure 8).

Figure 7: Disease association analysis of overlapping targets showing relevance to neurological and psychiatric disorders.




Figure 8: Cell-type enrichment analysis indicating predominant expression in neuronal cell populations.

DISCUSSION

The present study demonstrates that *N. jatamansi* exerts its effects through multiple targets and pathways associated with ADHD. Dopamine-related genes such as DRD2 and DRD4 suggest its role in improving attention and behavioral control.

Serotonergic and noradrenergic pathways further support its role in mood regulation. The involvement of BDNF indicates a role in neurodevelopment and synaptic plasticity.

Additionally, inflammatory markers such as TNF and NFKB1 suggest anti-inflammatory effects, which may contribute to its neuroprotective action.

Overall, the findings support a multi-target mechanism involving neurotransmission, neurodevelopment, and inflammation.

CONCLUSION

Nardostachys jatamansi acts through multiple biological pathways relevant to ADHD. Its effects on neurotransmitter systems, neurodevelopment, and inflammation support its potential as a complementary therapeutic option.

REFERENCES:

1. Faraone SV, Biederman J. Attention-deficit hyperactivity disorder. *Lancet*. 2018;391(10122):1240–52.
2. Arnsten AF. The neurobiology of attention-deficit/hyperactivity disorder. *Nat Rev Neurosci*. 2009;10(6):410–22.
3. Cortese S. Pharmacologic treatment of attention deficit– hyperactivity disorder. *N Engl J Med*. 2020;383(11):1050–6.
4. Bhattarai S, Chaudhary RP, Taylor RS. Ethnomedicinal plants used in central

Network Pharmacology-Based Investigation into the Multi-Target Mechanisms of *Nardostachys jatamansi* in the Treatment of ADHD

- Nepal. J Ethnopharmacol. 2005;102(2):123–6.
5. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol.* 2008;4(11):682–90.
 6. Daina A, Michielin O, Zoete V. SwissADME: a web tool to evaluate pharmacokinetics and drug-likeness. *Sci Rep.* 2017;7:42717.
 7. Gfeller D, Grosdidier A, Wirth M, et al. SwissTargetPrediction: a web server for target prediction. *Nucleic Acids Res.* 2014;42(W1):W32–8.
 8. Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite. *Curr Protoc Bioinformatics.* 2016;54(1):1.30.1–33.
 9. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks. *Nucleic Acids Res.* 2019;47(D1):D607–13.
 10. Zhou Y, Zhou B, Pache L, et al. Metascape provides a resource for systems-level datasets. *Nat Commun.* 2019;10(1):1523.
 11. Piñero J, Bravo À, Queralt-Rosinach N, et al. DisGeNET: a platform for disease-associated genes. *Nucleic Acids Res.* 2017;45(D1):D833–9.